RATIONALE: It has been reported that each of three drugs effective in treating bipolar disorder (lithium, carbamazepine, and valproate) decreases the turnover of arachidonic acid (AA, 20:4n-6) in brain phospholipids of the awake rat. It is also known that lithium and carbamazepine do so without decreasing the turnover of docosahexaenoic acid (DHA, 22:6n-3). OBJECTIVE: The aim of this study was to see whether valproate also specifically targets the turnover of AA but not of DHA in brain phospholipids. METHODS: Valproate was administered (200 mg kg(-1), i.p.) to rats for 30 days to produce a therapeutically relevant plasma concentration and then determine its effect compared with that of vehicle on incorporation and turnover rates of DHA in brain phospholipids. In unanesthetized rats that had received valproate or vehicle, [1-14C]DHA was infused intravenously, and arterial blood plasma was sampled until the animal was killed at 5 min; and its brain, after being microwaved, was subjected to chemical and radiotracer analysis. RESULTS: Using equations derived from our fatty acid model, it was found that chronic valproate compared with vehicle did not alter the rate of incorporation or turnover of DHA in brain phospholipids. Valproate-treated animals had higher concentrations of linoleic acid (18:2n-6) in several brain phospholipids, supporting the hypothesis that it alters brain n-6 fatty acid metabolism. CONCLUSIONS: The results, comparable to published findings following chronic administration of lithium and carbamazepine to rats, support the hypothesis that drugs are effective against mania in bipolar disorder act by downregulating incorporation and turnover of AA, but not of DHA, in brain phospholipids.
RATIONALE: It has been reported that each of three drugs effective in treating bipolar disorder (lithium, carbamazepine, and valproate) decreases the turnover of arachidonic acid (AA, 20:4n-6) in brain phospholipids of the awake rat. It is also known that lithium and carbamazepine do so without decreasing the turnover of docosahexaenoic acid (DHA, 22:6n-3). OBJECTIVE: The aim of this study was to see whether valproate also specifically targets the turnover of AA but not of DHA in brain phospholipids. METHODS:Valproate was administered (200 mg kg(-1), i.p.) to rats for 30 days to produce a therapeutically relevant plasma concentration and then determine its effect compared with that of vehicle on incorporation and turnover rates of DHA in brain phospholipids. In unanesthetized rats that had received valproate or vehicle, [1-14C]DHA was infused intravenously, and arterial blood plasma was sampled until the animal was killed at 5 min; and its brain, after being microwaved, was subjected to chemical and radiotracer analysis. RESULTS: Using equations derived from our fatty acid model, it was found that chronic valproate compared with vehicle did not alter the rate of incorporation or turnover of DHA in brain phospholipids. Valproate-treated animals had higher concentrations of linoleic acid (18:2n-6) in several brain phospholipids, supporting the hypothesis that it alters brain n-6 fatty acid metabolism. CONCLUSIONS: The results, comparable to published findings following chronic administration of lithium and carbamazepine to rats, support the hypothesis that drugs are effective against mania in bipolar disorder act by downregulating incorporation and turnover of AA, but not of DHA, in brain phospholipids.
Authors: Ho-Joo Lee; Sandra Ghelardoni; Lisa Chang; Francesca Bosetti; Stanley I Rapoport; Richard P Bazinet Journal: Neurochem Res Date: 2005-05 Impact factor: 3.996
Authors: M A Contreras; M C Chang; T A Rosenberger; R S Greiner; C S Myers; N Salem; S I Rapoport Journal: J Neurochem Date: 2001-12 Impact factor: 5.372
Authors: Victor L Marcheselli; Song Hong; Walter J Lukiw; Xiao Hua Tian; Karsten Gronert; Alberto Musto; Mattie Hardy; Juan M Gimenez; Nan Chiang; Charles N Serhan; Nicolas G Bazan Journal: J Biol Chem Date: 2003-08-15 Impact factor: 5.157
Authors: Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard Journal: J Biol Chem Date: 2011-10-06 Impact factor: 5.157
Authors: Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport Journal: Neuropharmacology Date: 2011-08-03 Impact factor: 5.250
Authors: Jakob A Shimshoni; Mireille Basselin; Lei O Li; Rosalind A Coleman; Stanley I Rapoport; Hiren R Modi Journal: Biochim Biophys Acta Date: 2010-12-22
Authors: Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger Journal: Psychopharmacology (Berl) Date: 2005-12-13 Impact factor: 4.530
Authors: Epolia Ramadan; Angelo O Rosa; Lisa Chang; Mei Chen; Stanley I Rapoport; Mireille Basselin Journal: J Lipid Res Date: 2010-04-13 Impact factor: 5.922
Authors: Mireille Basselin; Angelo O Rosa; Epolia Ramadan; Yewon Cheon; Lisa Chang; Mei Chen; Deanna Greenstein; Mary Wohltmann; John Turk; Stanley I Rapoport Journal: J Lipid Res Date: 2010-08-04 Impact factor: 5.922
Authors: Edmund A Reese; Yewon Cheon; Epolia Ramadan; Hyung-Wook Kim; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport; Ameer Y Taha Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2012-07-27 Impact factor: 4.006